Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's) but though they protect the heart and kidney, a significant percentage of patients develop a dangerous side effect; high potassium levels in the blood, a condition known as hyperkalemia. 

Elevated potassium puts patients at risk of death from cardiac arrhythmias. Lacking a drug to treat the problem, doctors either stop these beneficial drugs or may use kidney dialysis to quickly lower the potassium.

It is estimated that more than 20 million people in the U.S. have chronic kidney disease in varying levels of severity. Risk increases with age, and the disease is most common in adults over 70, particularly those with diabetes. Between 5 percent and 30 percent of patients, depending on the type and stage of chronic kidney disease and whether they are treated with one or more RAASI's, may develop a high potassium condition.

Two national studies of ZS-9, a new oral drug that has been tested in more than 1,000 patients with high blood potassium, had a subgroup of patients with chronic kidney disease treated with RAASI's. Results of the ZS-9 studies were reported in recent months in the New England Journal of Medicine and the Journal of the American Medical Association.

"Dialysis is logistically difficult for patients, requires a catheter and is expensive," said Wajeh Y. Qunibi, M.D., a professor of medicine in the School of Medicine at The University of Texas Health Science Center at San Antonio,  at the National Kidney Foundation Spring Clinical Meetings in Dallas. "In our studies, patients took a dose by mouth three times daily with meals, and potassium normalized in 98 percent of them within 48 hours. This is a major change in the way to treat hyperkalemia."